For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | - | 730,000 | 695,000 | 3,250 |
| Research and development | 62,931,000 | 54,196,000 | 52,614,000 | 40,887,500 |
| General and administrative | 10,686,000 | 10,391,000 | 10,820,000 | 9,637,000 |
| Total operating expenses | 73,617,000 | 64,587,000 | 63,434,000 | 50,524,500 |
| Operating loss | -73,617,000 | -63,857,000 | -62,739,000 | -48,769,500 |
| Investment and other income, net | 6,573,000 | 7,257,000 | 8,943,000 | 9,303,750 |
| Net loss | -67,044,000 | -56,600,000 | -53,796,000 | -38,580,666.667 |
| Unrealized gain on marketable securities | 426,000 | -229,000 | 254,000 | -1,167,333.333 |
| Comprehensive loss | -66,618,000 | -56,829,000 | -53,542,000 | -39,748,000 |
| Earnings per share, basic | -1.01 | -0.85 | -0.81 | -0.603 |
| Earnings per share, diluted | -1.01 | -0.85 | -0.81 | -0.603 |
| Weighted average number of shares outstanding, basic | 66,420 | 66,392 | 66,383 | -633 |
| Weighted average number of shares outstanding, diluted | 66,420 | 66,392 | 66,383 | -633 |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)